Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Lung Cancer

Despite guideline recommendations, a retrospective study found inadequate biomarker testing rates to direct targeted therapy.
Researchers highlighted promising research into early-stage diagnostics and therapies for NSCLC harboring the KRAS G12C mutation discussed in a review article.
A recent study found that chronic pneumonitis is a rare complication of immune checkpoint inhibitor therapy in patients with NSCLC.
A retrospective analysis demonstrated a 10-point difference in receipt of NGS testing between white and black patients with NSCLC.
Lung cancer remains the leading cause of cancer death worldwide, but the treatment landscape is rapidly evolving. In the past 10 years alone, the number of drugs approved by the FDA for non–small-cell lung cancer (NSCLC) has exceeded the previous 10 decades combined.
Recently released study results report similar chemo-immunotherapy outcomes in KRAS-mutant NSCLC subtypes and poor results in patients with concurrent STK11 and/or KEAP1 mutations.
A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy.
Subgroup analysis of CodeBreaK 100 trial results found that sotorasib achieved a response in pretreated patients with KRASG12C-mutated NSCLC subtypes.
Results from an incidental lung nodule program implemented in a community healthcare system demonstrates this program detects lung cancer in patients who are otherwise ineligible for LDCT screening.
Page 1 of 13
Results 1 - 10 of 128